Editorial review: Targets for glioma treatment: From bench to bedside

Current Opinion in Oncology

Volumn 20, Issue 6, 2008, Pages 650-651

  Sanson, Marc ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Angiogenesis; Glioma; Stem cells; Targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; ERLOTINIB; GEFITINIB; IRINOTECAN;

CANCER CHEMOTHERAPY; CELL HETEROGENEITY; CELL PROLIFERATION; CELL RENEWAL; COMBINATION CHEMOTHERAPY; DRUG POTENTIATION; GLIOBLASTOMA; HUMAN; MOLECULAR MECHANICS; PRIORITY JOURNAL; REVIEW; STEM CELL; TUMOR CELL; TUMOR GENE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL PROLIFERATION; GLIOMA; HUMANS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55749111542     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328313e188     Document Type: Review

References (13)

1. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90:1473-1479.
2. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003.
3. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353:2012-2024.
4. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007; 318:287-290.
5. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008; 5:e8.
6. Vredenburgh JJ, Desjardins A, Hemdon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25:4722-4729.
7. Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumours. Nat Rev Neurosci 2007; 8:610-622.
8. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66:7843-7848.
9. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD 133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5:67.
10. Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related 'self-renewal' signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008; 26:3015-3024.
11. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-760.
12. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006; 444:761-765.
13. Horvath S, Zhang B, Carlson M, et al. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A 2006; 103:17402-17407.